ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,039.31
-0.47%
US Tech 100
20,882.00
0.05%
Dow Jones
44,713.52
-0.31%
Brent Oil
75.575
-0.45%
Bitcoin
105,264.87
1.47%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. RAPT Therapeutics Inc (RAPT) Quote

RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

NASDAQ
1.17
-0.01
(-0.85%)
Closed January 30 4:00PM
Delayed by 15 minutes
1.18
0.01
(0.85%)
After Hours: 7:32PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.18
Bid
1.14
Ask
1.21
Volume
2,695,995
1.135 Day's Range 1.20
0.78925 52 Week Range 27.35
Market Cap
41.251M
Previous Close
1.18
Open
1.18
Last Trade
1000
@
1.18
(formt)
Last Trade Time
Financial Volume
$ 3,093,592
VWAP
1.1475
Average Volume (3m)
3,889,862
Shares Outstanding
34,958,253
Dividend Yield
-
PE Ratio
-0.35
Earnings Per Share (EPS)
-3.34
Revenue
-
Net Profit
-116.8M

About RAPT Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rapt.com
Headquarters
Dover, Delaware, USA
Founded
-
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was $1.18. Over the last year, RAPT Therapeutics shares have traded in a share price range of $ 0.78925 to $ 27.35.

RAPT Therapeutics currently has 34,958,253 shares outstanding. The market capitalization of RAPT Therapeutics is $41.25 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.35.

Ask ADVFN Intelligence (AI)

RAPT Latest News

More News

Form 424B3 - Prospectus [Rule 424(b)(3)]

January 28 2025
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

January 28 2025
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

January 21 2025
Edgar (US Regulatory)

Form 8-K - Current report

January 13 2025
Edgar (US Regulatory)

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

January 09 2025
GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

January 06 2025
Edgar (US Regulatory)

Form 8-K - Current report

January 06 2025
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

January 06 2025
Edgar (US Regulatory)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

January 06 2025
GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities

January 03 2025
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-1.666666666671.21.281.1158155571.18279032CS
4-0.41-25.7861635221.591.7851.06512487851.33761159CS
12-1.4-54.26356589152.583.320.7892538898621.67097067CS
26-2.14-64.45783132533.323.480.7892518326491.71162813CS
52-24.21-95.352500984625.3927.350.7892514180513.95977641CS
156-18.98-94.146825396820.1632.450.789257136269.46453328CS
260-44.27-97.40374037445.4546.490.7892555113414.28355872CS

RAPT - Frequently Asked Questions (FAQ)

What is the current RAPT Therapeutics share price?
The current share price of RAPT Therapeutics is $ 1.18
How many RAPT Therapeutics shares are in issue?
RAPT Therapeutics has 34,958,253 shares in issue
What is the market cap of RAPT Therapeutics?
The market capitalisation of RAPT Therapeutics is USD 41.25M
What is the 1 year trading range for RAPT Therapeutics share price?
RAPT Therapeutics has traded in the range of $ 0.78925 to $ 27.35 during the past year
What is the PE ratio of RAPT Therapeutics?
The price to earnings ratio of RAPT Therapeutics is -0.35
What is the reporting currency for RAPT Therapeutics?
RAPT Therapeutics reports financial results in USD
What is the latest annual profit for RAPT Therapeutics?
The latest annual profit of RAPT Therapeutics is USD -116.8M
What is the registered address of RAPT Therapeutics?
The registered address for RAPT Therapeutics is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the RAPT Therapeutics website address?
The website address for RAPT Therapeutics is www.rapt.com
Which industry sector does RAPT Therapeutics operate in?
RAPT Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DGNXDiginex Ltd
$ 49.18
(228.09%)
3.34M
SLXNSilexion Therapeutics Corporation
$ 3.1301
(131.86%)
330.45M
KRKR36Kr Holdings Inc
$ 9.10
(114.12%)
23.61M
SPGCSacks Parente Golf Inc
$ 0.6001
(57.92%)
52.17M
XFORX4 Pharmaceuticals Inc
$ 0.7542
(56.54%)
42.5M
ZKINZK International Group Co Ltd
$ 0.4813
(-41.21%)
3.1M
MGOLMGO Global Inc
$ 0.1019
(-38.73%)
70.52M
BACKIMAC Holdings Inc
$ 0.7869
(-35.50%)
2.37M
EYENEyenovia Inc
$ 0.03695
(-35.18%)
25.31M
HAOHaoxi Health Technology Ltd
$ 2.52
(-31.89%)
484.94k
NVDANVIDIA Corporation
$ 123.70
(-4.10%)
466.94M
SLXNSilexion Therapeutics Corporation
$ 3.1301
(131.86%)
330.45M
OCEAOcean Biomedical Inc
$ 0.249929
(-24.26%)
186.52M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.428
(-6.98%)
148.12M
RIMEAlgorhythm Holdings Inc
$ 0.0259
(-16.18%)
138.96M

RAPT Discussion

View Posts
Monksdream Monksdream 4 weeks ago
RAPT, under $2
👍️0
tbonaces80 tbonaces80 1 month ago
Buy this. Smart money in. 
👍️0
tbonaces80 tbonaces80 1 month ago
Gonna breakout above $2.11. Hold for major move. Shares gobbled on this wedge
👍️0
glenn1919 glenn1919 1 month ago
RAPT......................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 month ago
$2.20 + 20%
👍️0
tbonaces80 tbonaces80 1 month ago
Wainwright ups price to $10. This will be going parabolic 
👍️0
tbonaces80 tbonaces80 1 month ago
We go hard this week. Too many Capital firms bought in. Load the boat $6-$10 easy
👍️0
tbonaces80 tbonaces80 1 month ago
This will hit $6 easily. Analysts know. Huge funding.  Foully loaded. 
👍️0
PonkenPlonken PonkenPlonken 1 month ago
@tbonaces80 @Princess17
What do you two think about this?
150 million pp says massively misunderstood story? 140mn historical volume too...
👍️0
tbonaces80 tbonaces80 1 month ago


👍️0
tbonaces80 tbonaces80 1 month ago
Load zone. 
👍️0
Princess17 Princess17 1 month ago
👍🏻 looks good 
👍️0
tbonaces80 tbonaces80 1 month ago
Upgrade. Wells. Yup 
👍️0
PonkenPlonken PonkenPlonken 1 month ago
see chart and compare PP to market cap
must be massively misunderstood

also had a license agreement today
Regards
👍️0
bigbux1 bigbux1 1 month ago
What am I missing? They just did a private placement of 100,000,000 shares of common stock at a purchase price of $0.85 per share and this soars past 1.50?
👍️0
Mister Mr Mister Mr 1 month ago
Keep pumping! Let's go!!!
👍️0
glenn1919 glenn1919 1 month ago
rapt........................https://stockcharts.com/h-sc/ui?s=rapt&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 1 month ago
https://www.globenewswire.com/news-release/2024/12/23/3001133/0/en/RAPT-Therapeutics-Announces-150-Million-Private-Placement.html
wow!
market cap 30 million no discount
👍️0
Invest-in-America Invest-in-America 1 month ago
RAPT:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175569055
👍️0
tw0122 tw0122 1 month ago
RAPT up 15% news and TRAW also up $13.77 + 150% TRAW up big
👍️0
glenn1919 glenn1919 2 months ago
RAPT.........................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
RAPT under $3
👍️0
Monksdream Monksdream 5 months ago
RAPT new 52 week low
👍️0
Monksdream Monksdream 5 months ago
RAPT new 52 low
👍️0
Monksdream Monksdream 6 months ago
RAPT under $4
👍️0
Monksdream Monksdream 9 months ago
RAPT new 52 week
👍️0
Monksdream Monksdream 9 months ago
RAPT under $10
👍️0
tickersym tickersym 11 months ago
Bargin prices!! Lets go!!
👍️0
Stockexpertpro Stockexpertpro 11 months ago
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
👍️0
StockLogistics StockLogistics 2 years ago
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
👍️0
StockLogistics StockLogistics 3 years ago
A ton of insider buying last week
👍️0
StockLogistics StockLogistics 3 years ago
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
👍️0
Glider549 Glider549 4 years ago
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
👍️0
weasel4339 weasel4339 4 years ago
It's way up after hours bud
👍️0
Glider549 Glider549 4 years ago
Can't believe some of you did not take profits near the close.
Greed will kill ya.
👍️0
pennyfinder pennyfinder 4 years ago
Will do
👍️0
weasel4339 weasel4339 4 years ago
I'll keep n eye out. Let me knoe if u hear something about the price
👍️0
pennyfinder pennyfinder 4 years ago
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
👍️0
weasel4339 weasel4339 4 years ago
This considered dilution?
👍️0
pennyfinder pennyfinder 4 years ago
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
👍️0
make it happen make it happen 4 years ago
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
👍️0
pennyfinder pennyfinder 4 years ago
Offering AH or tomorrow pre
👍️0
make it happen make it happen 4 years ago
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
👍️0
StockLogistics StockLogistics 4 years ago
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
👍️0
Roadtojourney Roadtojourney 5 years ago
Not even 6 months old and already offering??
👍️0
crudeoil24 crudeoil24 5 years ago
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
👍️0
crudeoil24 crudeoil24 5 years ago
42.00 > hod.

RAPT
👍️0

Your Recent History

NASDAQ
RAPT
RAPT Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads